– Announced positive 12-month topline results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy –
– Advancing Phase 2 trial of EDG-5506 in Becker muscular. -Today at 08:03 am- MarketScreener
– Sustained positive trend in North Star Ambulatory Assessment (NSAA) scores relative to BMD natural history –
– Significant decreases in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers associated with skeletal muscle damage–
– EDG-5506 was well-tolerated at all doses –
– Company continuing to enroll patients with BMD in the CANYON Phase 2 trial which now includes a pivotal cohort called GRAND CANYON –
– Edgewise leadership to discuss ARCH findings on Tuesday, June 27 at 8:30 a.m. Eastern Time at virtual investor event –
Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.